Vicore Pharma Holding (NASDAQ:VCRE) Shares Shorted: Short Interest Down 75.7% in October

Vicore Pharma Holding (NASDAQ:VCRE) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 1,028 shares, a decline of 75.7% from the September 30th total of 4,238 shares. Based on an average daily volume of 27,277 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VCRE. Wall Street Zen upgraded shares of Vicore Pharma to a “hold” rating in a report on Saturday, October 24th. Jefferies Financial Group assumed coverage on Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Weiss Ratings initiated coverage on Vicore Pharma in a research note on Thursday, October 8th. They set a “sell (e-)” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $25.00.

Vicore Pharma Price Performance

Vicore Pharma stock traded up $0.42 on Thursday, hitting $10.18. 4,789 shares of the stock traded hands, compared to its average volume of 27,190. Vicore Pharma has a 1 year low of $7.88 and a 1 year high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last issued its quarterly earnings results on Friday, August 21st. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million for the quarter.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.

Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.